BTC Health Limited


BTC Health LimitedBTC Health (ASX:BTC) is a listed entity on the ASX and is a Pooled Development Fund, registered under the Pooled Development Funds Act 1992. It is a high-growth company, focused on making world-class innovative medical products available to patients in Australia and New Zealand.



BTC Health Limited (ASX:BTC) Chairmans Address and 2021 AGM Presentation

🕔11/23/2021 1:58:38 PM 24261

Ladies and gentlemen, I am pleased to report that BTC Health Limited (ASX:BTC) has achieved a number of milestones over the past 12 months, including a greater penetration of our products within hospitals.

Read Full Article

BTC Health Limited (ASX:BTC) Shareholder Update - September 2021

🕔9/3/2021 9:23:17 AM 16122

I am pleased to provide you with a detailed update on BTC Health Limited's (ASX:BTC) investments, along with an operational update of BTC's wholly owned investee companies.

Read Full Article

BTC Health Limited (ASX:BTC) Annual Report - 30 June 2021

🕔8/17/2021 5:24:28 PM 16233

The primary objective for BTC Speciality Health is to increase market share through organic growth. New products will continue to be sourced by BioImpact and will enable BTC Speciality Health to expand its product range within pain management and critical care.

Read Full Article

BTC Health Limited (ASX:BTC) Acquires Exclusive Distribution Rights for Bronchitol(R) and Aridol(R) from Pharmaxis

🕔7/6/2021 10:44:41 AM 19787

BTC Health Limited (ASX:BTC) is pleased to announce its investee company, BioImpact Pty Ltd, has acquired exclusive distribution rights for specialty respiratory brands Bronchitol(R) and Aridol(R) from Pharmaxis (ASX:PXS) in Australia, New Zealand, Singapore, Malaysia, Hong Kong and South Korea (Bronchitol(R) only).

Read Full Article

BTC Health Limited (ASX:BTC) $2.5m Capital Raise to Acquire the Distribution Rights to Bronchitol(R) and Aridol(R)

🕔7/5/2021 1:22:33 PM 18901

BTC Health Limited (ASX:BTC) is pleased to announce the receipt of binding firm commitments for a $2.5 million private placement to fund the acquisition of exclusive distribution rights to Bronchitol(R) and Aridol(R) in Australia, New Zealand, Malaysia, Hong Kong and Singapore.

Read Full Article

Stem Cell Sciences Grants Lexicon Genetics Exclusive IRES Licence

🕔11/4/2005 10:55:28 AM 2097

The board of Biotech Capital (ASX: BTC) announced that its investee company (Stem Cell Sciences plc ("SCS") has concluded an agreement with the US-Based company Lexicon Genetics ("Lexicon"). Lexicon is a biopharmaceutical company focused on the discovery and development of treatments for a range of human diseases primarily using its proprietary gene knock out technology.

Read Full Article


  • This Page Viewed: (Last 7 Days: 25) (Last 30 Days: 110) (Since Published: 7701) 

Company Data

  • Level 1, 10 Oxley Road
    Hawthorn VIC 3122
  • Principal Sector
  • Health & Pharm 
  • Principal Industry
  • Biotechnology 
  • Listed
  • 2000/08/29 
  • Homepage
  • E:


Social Media